SLC3A2 and breast carcinoma: Despite our data demonstrating the prognostic and predictive utility of SLC7A5/SLC3A2 co-expression in ER+ breast cancer, the exact mechanism of how the heterodimeric complex of SLC7A5/SLC3A2 contributes to endocrine resistance is unclear and requires further mechanistic investigations.